Selvita presents results of its neurology program at the Alzheimer’s Association International Conference 2013

Kraków, 13 June 2013 – Selvita, a Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders, as well as drug discovery services, will present data from its new neurology program at the Alzheimer’s Association International Conference, which will take place on the 13th-18th July, 2013, in Boston, United States.

Data disclosed during this conference will include the most recent results from Selvita’s new, promising neurology program: SEL141 – a potentially first in-class program targeting DYRK1A, and other related kinases in tauopaties such as Alzheimer’s disease (AD) and Down syndrome.

The poster entitled “Targeting kinases hyperphosphorylating tau protein: elucidation of kinase inhibition profile most efficient in restoring physiological tau phosphorylation”, will be presented on Wednesday, 17th July from 11:45 a.m. – 2:15 pm, in the Exhibit Hall (abstract number: 41187). The abstract will be published in the online version of the “Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association” in mid-October 2013.

“We’re pleased to present the research progress from of our new neurology program at this well-recognized, global platform for news regarding advances in Alzheimer’s and dementia research – said Dr Krzysztof Brzózka, Selvita’s Chief Scientific Officer. Tauopathy, next to beta amyloidosis, constitutes the second hallmark of Alzheimer’s disease. Direct inhibition of protein kinases implicated in tau hyperphosphorylation constitutes one of the favourable strategies for disease modifying treatment of AD and other tauopaties. We aimed at elucidation of the tau kinase inhibition profiles that would most efficiently restore physiological tau phosphorylation levels”.

 

About Selvita
Selvita is a Polish, biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders, as well as provision of drug discovery services. It was established in 2007 and currently employs 150 people, including over 50 PhDs. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2014. The most advanced programs at Selvita are SEL103 for the symptomatic treatment of Alzheimer’s disease, partnered with Orion Pharma, SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in hematopoietic tumors, SEL120, focused on first-in-class small molecule inhibitor of cyclin dependent kinase: CDK8, and SEL128, aimed at development of inhibitors of several novel kinases in cancer, involved with signal transduction and cancer metabolism. Other innovative projects currently in development include SEL141, an early stage discovery program of a series of DYRK1A kinase inhibitors with therapeutic potential in the treatment of tauopathies, including Alzheimer’s disease and Down syndrome, and SEL212, NALP3 inflammasome modulators for the treatment of autoinflammatory and autoimmune disorders. Additional information about Selvita can be found on https://selvita.com.
 
Media contact:
Natalia Baranowska
natalia.baranowska@selvita.com
+48 784 069 418  
Click to share!: